Loading...
NPI 1891157079 · Chicago, IL · Molecular Genetic Pathology (Pathology) Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Erica Vormittag-nocito is a molecular genetic pathology (pathology) physician provider located in Chicago, Illinois. This profile covers 4 Medicare and 3 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Erica Vormittag-nocito |
| Address | 710 N Fairbanks Ct Ste 2-454 |
| City | Chicago |
| State | IL |
| ZIP | 60611 |
| Taxonomy | Molecular Genetic Pathology (Pathology) Physician |
| NPI Enumerated | March 25, 2016 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $56.4K |
| Medicaid | $3.1K |
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
4 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0452 | Molecular pathology procedure; physician interpretation and report | 1,060 | $40 | $39.2K |
| 88366 | The lab analyst applies a single in situ hybridization multiplex probe stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a… | 270 | $50 | $13K |
| 88387 | The analyst performs all the technical steps to examine a tissue specimen using normal sight, dissect out the part of the specimen needed for testing, and then prepare the tissue for nonmicroscopic… | 170 | $20 | $3.5K |
| 88291 | A qualified provider, typically a pathologist, submits an interpretation and report of cytogenetic and molecular cytogenetic testing commonly performed by lab analysts. | 40 | $30 | $1.1K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 4 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
3 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 88366 | The lab analyst applies a single in situ hybridization multiplex probe stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a… | 70 | $40 | $2.7K |
| 88291 | A qualified provider, typically a pathologist, submits an interpretation and report of cytogenetic and molecular cytogenetic testing commonly performed by lab analysts. | 10 | $20 | $220 |
| G0452 | Molecular pathology procedure; physician interpretation and report | 10 | $10 | $110 |
How this provider's Medicaid billing volume and revenue compare to other Illinois providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Illinois median
3 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 88366 | The lab analyst applies a single in situ hybridization multiplex probe stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a… | 2 | 10 | 70 | $40 | $6K |
| 88291 | A qualified provider, typically a pathologist, submits an interpretation and report of cytogenetic and molecular cytogenetic testing commonly performed by lab analysts. | 7 | 10 | 30 | $10 | $1.9K |
| G0452 | Molecular pathology procedure; physician interpretation and report | 8 | 10 | 160 | $1 | $900 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.